Proactive Investors - Run By Investors For Investors

Namaste Technologies granted management cease trade order

During the period in which the MCTO is effective, the general investing public, who are not insiders of the company, can continue to trade
Trader..
Namaste's CEO and CFO will not be able to trade the firm's shares until the annual filings have been filed by the company and the MCTO has been lifted

Namaste Technologies Inc (CVE:N) (OTCMKTS:NXTTF) says it has been granted a management cease trade order (MCTO).

The MCTO was applied for after the Toronto cannabis company said it was not in a position to file its audited annual financial statements for the fiscal year ending November 30 and the related analysis by the filing deadline of April 1, 2019, as it had to permit sufficient time for Baker Tilly to complete its year-end audit.

READ: Namaste Technologies taps Baker Tilly as new auditor

During the period in which the MCTO is effective, the general investing public, who are not insiders of the company,  can continue to trade.

However, Namaste's CEO and CFO will not be able to trade the firm's shares until the annual filings have been filed by the company and the MCTO has been lifted.

Namaste said in today's statement that it expects to be able to complete the annual filings by May 31 this year.

Contact Giles at [email protected]

Follow him on Twitter@Gile74

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
Cameron Durrant
March 05 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
word cancer under magnifying glass
May 02 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use